Free Trial
NASDAQ:LEXX

Lexaria Bioscience 1/10/2025 Earnings Report

Lexaria Bioscience logo
$1.19 -0.04 (-3.25%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$1.20 +0.01 (+0.42%)
As of 05/2/2025 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lexaria Bioscience EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.12
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Lexaria Bioscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lexaria Bioscience Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Lexaria Bioscience's next earnings date is estimated for Friday, July 11, 2025, based on past reporting schedules.

Conference Call Resources

Lexaria Bioscience Earnings Headlines

Zacks Small Cap Has Pessimistic View of LEXX FY2025 Earnings
Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
Lexaria provides GLP-1 update following industry developments
See More Lexaria Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lexaria Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexaria Bioscience and other key companies, straight to your email.

About Lexaria Bioscience

Lexaria Bioscience (NASDAQ:LEXX) operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

View Lexaria Bioscience Profile

More Earnings Resources from MarketBeat